

Trading in SynAct Pharma's shares on Nasdaq Stockholm commences today

SynAct Pharma AB ("SynAct") today announced that its share (ticker: SYNACT) will start trading on Nasdaq Stockholm's main list today, July 12, 2022.

"SynAct Pharma has worked hard with its pipeline to make it to where it is today. To be traded on the main market is an important landmark and a stamp of quality for SynAct, which enables us to accelerate the development of our lead candidate drug AP1189 through our clinical programs in RA, NS and other chronic diseases and subsequent commercialization. The move gives us access to more international and institutional investors, who will be key to our ambitious growth plans," said Jeppe Øvlesen, CEO of SynAct Pharma.

SynAct's share will be traded in the Mid Cap segment and will retain both its ticker (SYNACT) and ISIN code (SE0008241491). In connection with the list change, there will be no offering or issue of new shares and shareholders of SynAct will not need to take any actions.

The English text is an unofficial translation of the original Swedish text. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.

For further information about SynAct Pharma AB, please contact: Jeppe Øvlesen

CEO, SynAct Pharma AB Phone: +45 28 44 75 67

Mail: joo@synactpharma.com

Patrik Renblad

CFO, SynAct Pharma AB Phone: +46 707 47 97 68 Mail: par@synactpharma.com

About Us

About SynAct Pharma AB

SynAct Pharma AB conducts research and development in inflammatory diseases. The company has a platform technology based on a new class of drug candidates aimed at acute deterioration in chronic inflammatory diseases with the primary purpose of stimulating natural healing mechanisms. For more information: www.synactpharma.com.

Attachments

Trading in SynAct Pharma's shares on Nasdaq Stockholm commences today